octapotassium,dioxidoboranylformonitrile | CAS:261356-49-4

We serve octapotassium,dioxidoboranylformonitrile CAS:261356-49-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
octapotassium,dioxidoboranylformonitrile

Chemical Name:octapotassium,dioxidoboranylformonitrile
CAS.NO: 261356-49-4
Molecular Formula:C4B4K8N4O8
Molecular Weight: 588.09500
 
Synonyms:
octapotassium,dioxidoboranylformonitrile
Borate(1-),tetrakis(cyano-kC)-,potassium (9CI)
Borate(1-),tetrakis(cyano-kC)-,potassium (1:1)
Potassium tetracyanoborate
Potassium tetracyanoborate(1-)
 
Physical and Chemical Properties:
Vapor pressure: 740mmHg at 25°C
Boiling point: 25.7ºC at 760mmHg
 
 
Specification:
Appearance: /
Purity: ≥98%
Water:≤0.5% 
 
Packing:10g/bottle,100g/bottle ,1000g/bottle .
Storage:Keep away from light, keep the container tightly closed, and place in a well-ventilated place, separate from strong oxidants.
Application:chemical raw material



Contact us for information like Tetracyanoethane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Potassium tetracyanoborate(1-) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,malonodinitrile dimer Use and application,tetracyanoethylene technical grade,usp/ep/jp grade.


Related News: Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers.L-Serine manufacturer Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers.Methyl 4-boronobenzoate supplier At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.1-Bromo-4-ethylbenzene vendor At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.The use of contrast agents is different from other drugs, and it needs to be used with corresponding equipment. In recent years, China is in the growth period of imaging equipment.